The Efficacy of a Combination Regimen in Patients With Mild to Moderate Probable Alzheimer's Disease
Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This is a national multicenter, double-blind, randomized, parallel-group trial of 12 months
in duration. Following a 4 week wash-out period, subjects will be randomized to one of 2
treatment groups: (1) galantamine CR 24 mg/day with dose-titration over twelve
weeks[maintenance phase from week 9], (2) a combination of galantamine CR 24 mg/day plus
memantine 10 mg b.i.d. with a dose titration of sixteen weeks (12 weeks for galantamine
[maintenance phase from week 9], additional 4 weeks for memantine).